Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ANDAs For Drug/Device Combos Face High Bar At US FDA; Epipen, Advair May Benefit

Jan 17 2017

• By Derrick Gingery

Related Content

Generic Firms Fear FDA Pill Size Guidance Helps Brands Stifle Competition

Aug 31 2015

EpiPen Generics: Woodcock Explains Injector Studies

Sep 22 2016

Complex ANDAs To Be Allowed Pre-Submission Product Meetings

Oct 24 2016

Mylan’s EpiPen Exclusivity Saved Again As Teva Reports CRL

Mar 01 2016

EpiPen Outrage In Congress Puts Spotlight On FDA Generic Review

Aug 30 2016

FDA Guidance Sheds Light On Human Factor Studies For Combo Products

Feb 05 2016

Stayin’ Alive: GSK Sees Options For Brand Advair In A Post-Generic World

Oct 26 2016

Related Companies

Viatris Inc.

Teva Pharmaceutical Industries Ltd.

CVS Health Corp.

Amneal Pharmaceuticals, Inc.

Sanofi

Kaléo Pharmaceutical Inc.

GSK plc

Additional Topics

United States Generic Drugs Regulation Drug Review Combination Products BioPharmaceutical

More from Generics

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.